Interesting.....
According to a note out of Bell Potter, its analysts have initiated coverage on this biopharmaceutical company's shares with a buy rating and $24.00 price target. The broker believes that Clinuvel is well-positioned for strong growth in the coming years thanks to its Scenesse product for erythropoietic protoporphyria (EPP). And with the company hoping to expand its use to treat other diseases and busy developing new products, Bell Potter is positive on its longer-term outlook. The Clinuvel share price is trading at $14.82 today.
Ann: CEO Letter to Shareholders, page-45
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.90 |
Change
-0.200(1.42%) |
Mkt cap ! $695.8M | |||
| Open | High | Low | Value | Volume |
| $14.08 | $14.12 | $13.86 | $1.006M | 72.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 210 | $13.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.94 | 576 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |